title: Expression of pituitary tumor transforming gene (PTTG) in human pituitary macroadenomas.
abstract: The purpose of this study was to elucidate the relationship between pituitary tumor transforming gene (PTTG) and invasiveness in pituitary macroadenomas and to determine the association between PTTG and both the tumor proliferative activity marker proliferation cell nuclear antigen (PCNA) and the angiogenic factor basic fibroblast growth factor. A total of 70 patients with pituitary adenomas who underwent transsphenoidal or craniotomy surgical resection were enrolled. The average age were 42.5 ± 13.7 years (17-64 years) for the invasive group and 46.8 ± 12.1 years (16-71 years) for the non-invasive group, with no significant difference (P=0.179) between the two groups. RT-PCR analysis of a group of pituitary macroadenomas demonstrated that the expression levels of PTTG and PCNA in invasive pituitary adenomas were significantly higher than in non-invasive pituitary adenomas. Both factors are both closely related to the invasive growth of pituitary adenomas and may possibly serve as important markers of this growth. In conclusion, PTTG may promote invasive tumor growth by stimulating pituitary adenomas proliferation. The mechanisms of tumor growth promotion and invasion of the surrounding structures by PTTG need to be further explored.
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6, Tiantan Xili, Beijing, 100050, Dongcheng District, China. jiawbj@yeah.net
authors: Wang
authors: W
authors: Jia
authors: Runchun
authors: R
authors: Lu
authors: Guijun
authors: G
authors: Jia
authors: Ming
authors: M
authors: Ni
authors: Zhiqing
authors: Z
authors: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D009367:Neoplasm Staging; D010911:Pituitary Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D064249:Securin; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D018809:Proliferating Cell Nuclear Antigen; D064249:Securin; C578002:pituitary tumor-transforming protein 1, human; D016222:Fibroblast Growth Factor 2
references: J Clin Endocrinol Metab. 1992 Dec;75(6):1436-41
references: 1464644
references: Exp Clin Endocrinol Diabetes. 2008 Feb;116(2):80-5
references: 18072009
references: Oncogene. 2012 Jun 28;31(26):3124-35
references: 22081074
references: Mol Endocrinol. 1999 Jan;13(1):156-66
references: 9892021
references: Acta Neuropathol. 2006 Jan;111(1):76-7
references: 16328520
references: Clin Endocrinol (Oxf). 1998 Jan;48(1):23-9
references: 9509064
references: Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8
references: 8232800
references: Clin Endocrinol (Oxf). 2006 Oct;65(4):536-43
references: 16984249
references: Mol Cancer. 2006 Nov 10;5:61
references: 17096843
references: Acta Neuropathol. 2006 Jan;111(1):71-2
references: 16328522
references: J Clin Endocrinol Metab. 2001 Feb;86(2):867-74
references: 11158059
references: Endocr Pathol. 1999 Autumn;10(3):229-235
references: 12114703
references: Nature. 1987 Apr 2-8;326(6112):515-7
references: 2882423
references: Histol Histopathol. 2007 Feb;22(2):219-26
references: 17149695
references: J Clin Endocrinol Metab. 1995 Mar;80(3):878-84
references: 7883846
references: Int J Surg Pathol. 2010 Feb;18(1):5-13
references: 20106827
references: Folia Histochem Cytobiol. 2006;44(1):37-41
references: 16584090
references: Eur J Endocrinol. 2003 Feb;148(2):203-11
references: 12590639
references: Exp Clin Endocrinol Diabetes. 2010 Feb;118(2):121-6
references: 19472104
references: J Clin Endocrinol Metab. 2010 Apr;95(4):1708-16
references: 20164287
references: Clin Med Res. 2006 Jun;4(2):130-7
references: 16809406
references: Mol Cell Endocrinol. 2007 Nov 15;278(1-2):1-6
references: 17928133
references: Arq Neuropsiquiatr. 2004 Jun;62(2B):437-43
references: 15273840
references: J Neurosurg. 1993 May;78(5):753-61
references: 8096873
references: Nat Med. 1999 Nov;5(11):1317-21
references: 10546001
references: Endocr Pathol. 2001 Summer;12(2):163-9
references: 11579682
references: Chin J Cancer Res. 2012 Dec;24(4):275-83
references: 23359208
references: Cancer Res. 2007 Nov 1;67(21):10564-72
references: 17975001
references: Mol Endocrinol. 2005 Sep;19(9):2371-9
references: 15919720
references: Endocr Relat Cancer. 2007 Sep;14(3):887-900
references: 17914117
references: Tumori. 2003 Jan-Feb;89(1):54-9
references: 12729363
references: Surg Neurol. 2006 Feb;65(2):130-5; discussion 135
references: 16427401
references: Oncology (Williston Park). 1998 Sep;12(9):1307-12, 1315; discussion 1315-8
references: 9778677
references: Clin Endocrinol (Oxf). 2003 Feb;58(2):141-50
references: 12580928
references: Pituitary. 2009;12(3):256-60
references: 19003540
references: J Clin Endocrinol Metab. 1999 Feb;84(2):761-7
references: 10022450
references: Endocr Pathol. 2006 Summer;17(2):143-53
references: 17159247
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: Acta Radiol. 1997 Jan;38(1):30-6
references: 9059398
references: Endocr Relat Cancer. 2008 Sep;15(3):721-43
references: 18753362
references: J Clin Invest. 2002 Jan;109(2):277-83
references: 11805140
references: Endocr Relat Cancer. 2002 Jun;9(2):103-13
references: 12121834
references: Neuroendocrinology. 2006;83(3-4):179-88
references: 17047381
references: Ann Diagn Pathol. 2008 Aug;12(4):275-82
references: 18620995